09:02 AM EDT, 04/21/2026 (MT Newswires) -- Simulations Plus ( SLP ) said Tuesday it has entered into a funded research collaboration with Swiss contract development and manufacturing organization Lonza Group and the US Food and Drug Administration to advance predictive frameworks for complex oral drug formulations.

The collaboration aims to develop and validate a predictive framework for evaluating the in vivo performance of amorphous solid dispersion drug products, the company said.

Financial terms of the collaboration were not provided. Simulations Plus ( SLP ) said that the work is partly supported by the government agency.